- Home
- ASLE vs DMAC Comparison
ASLE vs DMAC Comparison
Compare ASLE & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASLE
- DMAC
- Stock Information
- Founded
- ASLE 2008
- DMAC 2000
- Country
- ASLE United States
- DMAC United States
- Employees
- ASLE N/A
- DMAC N/A
- Industry
- ASLE Industrial Specialties
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- ASLE Consumer Discretionary
- DMAC Health Care
- Exchange
- ASLE Nasdaq
- DMAC Nasdaq
- Market Cap
- ASLE 290.0M
- DMAC 321.5M
- IPO Year
- ASLE N/A
- DMAC N/A
- Fundamental
- Price
- ASLE $5.95
- DMAC $6.30
- Analyst Decision
- ASLE Hold
- DMAC Strong Buy
- Analyst Count
- ASLE 2
- DMAC 4
- Target Price
- ASLE $7.00
- DMAC $15.50
- AVG Volume (30 Days)
- ASLE 460.1K
- DMAC 315.3K
- Earning Date
- ASLE 11-06-2025
- DMAC 11-12-2025
- Dividend Yield
- ASLE N/A
- DMAC N/A
- EPS Growth
- ASLE N/A
- DMAC N/A
- EPS
- ASLE 0.11
- DMAC N/A
- Revenue
- ASLE $339,090,000.00
- DMAC N/A
- Revenue This Year
- ASLE $9.98
- DMAC N/A
- Revenue Next Year
- ASLE $8.15
- DMAC N/A
- P/E Ratio
- ASLE $53.36
- DMAC N/A
- Revenue Growth
- ASLE N/A
- DMAC N/A
- 52 Week Low
- ASLE $5.56
- DMAC $3.19
- 52 Week High
- ASLE $9.12
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- ASLE 22.00
- DMAC 47.59
- Support Level
- ASLE $5.86
- DMAC $5.26
- Resistance Level
- ASLE $6.20
- DMAC $6.47
- Average True Range (ATR)
- ASLE 0.24
- DMAC 0.43
- MACD
- ASLE -0.11
- DMAC -0.07
- Stochastic Oscillator
- ASLE 19.90
- DMAC 54.22
About ASLE AerSale Corporation
AerSale Corp is an integrated, diversified leader in aviation aftermarket products and services. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing a broad range of maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. The company operating segment includes Asset Management Solutions and TechOps. It generates maximum revenue from the Asset Management Solutions segment.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.